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Excitotoxic inactivation of constitutive oxidative
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Excitotoxicity, a critical process in neurodegeneration, induces oxidative stress and neuronal
death through mechanisms largely unknown. Since oxidative stress activates protein kinase
D1 (PKD1) in tumor cells, we investigated the effect of excitotoxicity on neuronal PKD1
activity. Unexpectedly, we find that excitotoxicity provokes an early inactivation of PKD1
through a dephosphorylation-dependent mechanism mediated by protein phosphatase-1
(PP1) and dual specificity phosphatase-1 (DUSP1). This step turns off the IKK/NF-κB/SOD2
antioxidant pathway. Neuronal PKD1 inactivation by pharmacological inhibition or lentiviral
silencing in vitro, or by genetic inactivation in neurons in vivo, strongly enhances excitotoxic
neuronal death. In contrast, expression of an active dephosphorylation-resistant PKD1 mutant
potentiates the IKK/NF-κB/SOD2 oxidative stress detoxification pathway and confers neu-
roprotection from in vitro and in vivo excitotoxicity. Our results indicate that PKD1 inacti-
vation underlies excitotoxicity-induced neuronal death and suggest that PKD1 inactivation
may be critical for the accumulation of oxidation-induced neuronal damage during aging and
in neurodegenerative disorders.
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Neuronal death by excitotoxicity is a critical process innumerous human neuropathologies, such as stroke,traumatic brain injury, epilepsy, Alzheimer's disease,
Parkinson's disease, Huntington's disease, amyotrophic lateral
sclerosis, and multiple sclerosis1. Therefore, intervening the
mechanistic steps that lead to excitotoxicity may protect the brain
in a broad range of acute and chronic central nervous system
pathologies.
Excitotoxicity originates by massive release of the excitatory
neurotransmitter glutamate. Overstimulation of postsynaptic
glutamate receptors, including the ionotropic N-methyl-D-aspar-
tate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole pro-
pionic acid (AMPA), and kainic acid (KA) receptors, overexcites
neurons and triggers pro-death cascades1–3. Primarily, excessive
influx of calcium ions occurs, followed by endoplasmic reticulum
stress, mitochondrial dysfunction, generation of high levels of
reactive oxygen species (ROS), and oxidative stress damage,
leading to neuronal death4–6.
Protein kinase D1 (PKD1), together with PKD2 and PKD3,
constitute a family classified within the calcium/calmodulin-
dependent protein kinase superfamily7. Numerous stimuli acti-
vate PKD through well-established pathways. In many cases this
activation is transient, but the mechanisms stopping sustained
stimulation remain unexplored7. Oxidative stress is an important
activator of PKD1 in cellular models, but its capacity to activate
this kinase in vivo is largely unknown.
Excitotoxic production of ROS elevates death-associated pro-
tein kinase (DAPK) activity, which provokes neuronal apoptosis
in cerebral ischemia and seizure models8. Accordingly, DAPK
absence protects neurons from excitotoxic insults9, 10. Of note,
DAPK can activate PKD in HeLa cells under oxidative stress
conditions11, thus suggesting that PKD activation may contribute
to cellular death.
In addition, oxidative stress can also elicit PKD1 activation,
determined by Ser916 autophosphorylation, through initial
phosphorylation by Abl and Src kinases (at Tyr469 and Tyr93,
respectively) and subsequent phosphorylation by protein
kinase C delta (PKCδ) of Ser744 and Ser748 (reviewed in ref.
12; see Scheme in Fig. 1a). This cascade promotes cellular
survival in non-neuronal tumor cells, through activation of I
kappaB kinase (IKK) and nuclear factor-kappaB (NF-κB) that
induces SOD2 transcription, a gene encoding the mitochon-
drial manganese-dependent superoxide dismutase (MnSOD)
involved in ROS detoxification13–17. However, the contribution
of NF-κB to neuronal physiopathology is highly controversial,
being associated to both neuroprotection and neurotoxicity18.
NF-κB can regulate genes involved either in neuronal survival
or in death19 and there is also some evidence of NF-κB acti-
vation by ROS and excitotoxicity in cultured primary neu-
rons20–22.
To date, to our knowledge there are no studies investigating
PKD1 activation by oxidative stress in neurodegeneration animal
models or in samples from human disease.
Whether excitotoxic oxidative stress produces PKD1 activation
in neurons, and whether this step leads to changes in neuronal
NF-κB activity is an important question that remains unan-
swered. Moreover, the molecular mechanisms involved in PKD
inactivation also remain unknown and the contribution of this
inactivation to pathophysiological processes has not been inves-
tigated. Here we show the existence of a constitutive neuronal
PKD1/IKK/NF-κB/SOD2 oxidative stress detoxification pathway
that is inactivated by phosphatase-dependent mechanisms during
excitotoxic neurodegeneration. Our study demonstrates that
PKD1 potentiates neuronal survival by helping neurons to fight
against oxidative stress through IKK and NF-κB.
Results
Excitotoxicity regulates neuronal PKD activity. Excitotoxic
concentrations of the NMDA receptor (NMDAR) agonist NMDA
together with its co-agonist glycine induce neuronal death23–25.
To investigate whether PKD is activated by excitotoxicity, we
stimulated cultured primary mature cortical neurons with NMDA
(50 μM) and glycine (10 μM), a treatment referred here as
“NMDA”, for different time periods and assessed Ser916 autop-
hosphorylation by immunoblot26 (Fig. 1a, b). PKD basal activity
increased 5 min after NMDA addition (Fig. 1b). Strikingly, 30
min and 1 h of treatment decreased p-Ser916 signal markedly
below that in control cells (Fig. 1b), indicating a rapid inactiva-
tion of PKD. Note that p-Ser916 band appeared as a doublet in
unstimulated neurons and that NMDA modified the intensity of
both bands (Fig. 1b). Lentiviral transduction of PKD1 or PKD2-
specific short hairpin RNA (shRNAs) indicated that the upper
and lower bands corresponded to PKD1 and PKD2, respectively,
and that the PKD antibody detected mainly PKD1 (Supplemen-
tary Fig. 1a). In addition, studies by RT-qPCR showed that PKD1
transcripts were more abundant than those for PKD2 and PKD3
in mature cultured neurons, and that excitotoxicity did not affect
their levels (Supplementary Fig. 1b, c) or those of total PKD
protein (Fig. 1b), suggesting that the observed results may reflect
changes in kinases and phosphatases (PPs) activities rather than
PKD degradation.
Importantly, non-excitotoxic doses of NMDA (≤10 μM) failed
to alter PKD activity (Supplementary Fig. 1d). Excitotoxicity was
confirmed by the processing of full-length (FL) brain Spectrin to
breakdown products (BDPs) by calpain, a protease activated
through NMDARs overstimulation27 (Fig. 1b), as well as
measuring neuronal viability (Supplementary Fig. 1e). This
neuronal death was not blocked by the caspase inhibitor zVAD,
suggesting its non-apoptotic nature (Supplementary Fig. 1f). In
addition, we detected an increase in ROS production after 1 h of
NMDA addition, when PKD appears inactive (Supplementary
Fig. 1g), indicating that excitotoxicity-induced ROS production is
not paralleled by sustained activation of PKD.
Excitotoxic neuronal death is coupled to stimulation of
extrasynaptic NMDARs28 where GluN2B is the major subunit29.
To investigate whether GluN2B is required for NMDA-mediated
regulation of PKD activity, we used a selective antagonist for this
subunit, ifenprodil (IFN)30. This inhibitor prevented activation
(Fig. 1c) and inactivation (Fig. 1d) of PKD. The generic NMDAR
antagonist DL-AP5 also blocked the regulation of PKD activity by
NMDA (Fig. 1c, d). Notably, DL-AP5 but not IFN increased PKD
basal activity (Fig. 1c, d), suggesting that activity of synaptic
NMDARs, likely through GluN2A, may contribute to PKD
dephosphorylation. As expected, both antagonists hampered the
excitotoxic process, as shown by the absence of Spectrin BDPs
after 1 h of NMDA (Fig. 1d).
Overactivation of NMDARs triggers a massive Ca2+ influx.
Buffering of extracellular Ca2+ with EGTA or treating neurons
with the Ca2+ ionophore A23187 demonstrated that the entry of
this ion was evoking PKD activity changes (Supplementary
Fig. 1h, i).
In conclusion, excitotoxicity drives a short activation followed
by a sharp inactivation of PKD that depends on overstimulation
of NMDARs containing GluN2B subunits through Ca2+ entry.
Phosphorylation-dependent excitotoxic regulation of PKD. To
determine the pathway of PKD activation, we analyzed PKC-
dependent activatory transphosphorylation of Ser744/Ser748, and
found it changed significantly showing a time-course of phos-
phorylation/dephosphorylation similar to that showed by p-
Ser916 (Fig. 1a, b; Supplementary Fig. 1j). In contrast to the
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transient PKD activation, excitotoxicity produced a rapid and
sustained activation of DAPK along NMDA treatment, as shown
by its gradual activatory dephosphorylation on Ser3089, 10
(Fig. 1b). Together, these results suggest that PKC, rather than
DAPK, is the kinase governing PKD activation changes in
excitotoxicity.
Under oxidative stress conditions, PKD stimulation mediated by
PKCδ phosphorylation is facilitated through Src family tyrosine
kinases (reviewed in ref. 12), where Tyr469 and Tyr93 are
phosphorylated by Abl and Src, respectively. To study PKD Src-
dependent tyrosine phosphorylation, we generated a novel
phosphospecific monoclonal antibody (mAb) targeting phosphory-
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This antibody detected the upper PKD1 band in neuronal pTyr93
immunoprecipitates and its signal followed a similar pattern of
phosphorylation/dephosphorylation as that for p-Ser916 following
NMDA addition in the precipitated immunocomplexes (Fig. 1e). It
is important to note that pTyr93 signal (and also that of pTyr469)
in neurons was strongly potentiated by tyrosine phosphatase
inhibitors (Supplementary Fig. 2a). These data suggest that tyrosine
PPs might be highly active in mature neurons and contribute to the
low level of detection of tyrosine phosphorylated residues unless
potent phosphatase inhibitors are used.
Next, we analyzed the effect of the general inhibitors of PKC and
Src, GF109203X (GFI) and PP2, respectively, finding that both
blocked excitotoxic PKD activation (Supplementary Fig. 3a).
Furthermore, rottlerin and SU6656, selective PKCδ and Src family
kinase inhibitors, showed the same effect (Fig. 1f, see quantification
in Supplementary Fig. 3b), indicating the specific participation of
both kinases on the early PKD activation induced by NMDA.
While several kinases involved in PKD activation have been
identified, the PPs mediating its inactivation remain unknown7.
We investigated how pharmacological inhibition of different PPs
could prevent excitotoxicity-induced PKD dephosphorylation.
We pretreated neurons with high concentrations of the serine/
threonine PPs inhibitor okadaic acid (OA, 500 nM) to inhibit PP1
and PP2A activities31 before overstimulating NMDARs. PKD was
maintained highly active in the presence of OA under basal
conditions or after NMDA addition (Fig. 1g). However, low
concentrations of OA (1 nM), able to block PP2A but not PP131,
or PP2B inhibitors did not prevent PKD inactivation (Supple-
mentary Fig. 3c, d). Treatment with the tyrosine PPs inhibitor
pervanadate (PV) also increased basal PKD activity and preserved
its activation after 1 h of NMDARs overstimulation (Fig. 1g). The
PV-induced increase at the higher molecular weight band of p-
Ser916 doublet suggested the presence of PKD1-tyrosine-
hyperphosphorylated forms in this band (Fig. 1g, solid arrow
head). Together, these results suggest a critical involvement of
PP1 and tyrosine PPs in the regulation of neuronal PKD basal
activity and in its inactivation during excitotoxicity. They also
indicate that activity of PKD in mature neurons might undergo
dynamic cycles of phosphorylation/dephosphorylation events due
to synaptic activity, likely with the participation of GluN2A
subunits and calcium. This fine dynamic synaptic modulation
would explain the substantial increases in PKD phosphorylation
and activity when all NMDARs or the PPs involved are blocked.
DAPK was dephosphorylated earlier than PKD (Fig. 1b),
suggesting that they are regulated by different PPs. However, the
kinetics of PKD dephosphorylation paralleled those of the
mitogen activated protein kinase p38 (Supplementary Fig. 3e
and refs. 32–34) suggesting both could be inactivated by the same
PPs. The dual specificity phosphatase-1 (DUSP1) and the brain
specific striatal-enriched protein tyrosine phosphatase (STEP) are
known p38 PPs activated during excitotoxicity and cerebral
ischemia35–39. We therefore investigated DUSP1 and STEP
contribution to excitotoxic PKD inactivation. STEP depho-
sphorylation leads to its activation detected by a mobility shift
from 61 kDa (STEP61) toward faster-migrating forms36, 37.
NMDAR overstimulation increased DUSP1 levels and STEP
activation in neurons, both changes paralleling PKD and p38
inactivation (Supplementary Fig. 3e).
Since PP1 can activate STEP downstream NMDARs overactiva-
tion36, 40, 41, we analyzed STEP activity in the presence of OA. We
observed that only PP1-inhibitory concentrations of OA blocked
STEP activation and led to the accumulation of p-p38 (Fig. 1g;
Supplementary Fig. 3c). PV treatment was also effective blocking
STEP activation and p38 dephosphorylation (Fig. 1g). In addition, OA
and PV decreased DUSP1 excitotoxic induction (Fig. 1g).
Finally, we transduced neurons with lentiviral particles
encoding a control shRNA (shC) or shRNA specific for either
Dusp1 (shDUSP1) or Step (shSTEP) silencing. Dusp1 knockdown
significantly hampered PKD excitotoxic dephosphorylation while
Step silencing had no effect (Fig. 1h, i). Of note, shDUSP1 exerted
a very similar action to that of PV, increasing the upper band of
p-Ser916 doublet, suggestive of DUSP1 acting on p-Tyr residues
within active PKD1 (Fig. 1h). Furthermore, Dusp1 but not Step
knockdown (Fig. 1h), as PV treatment (Fig. 1g), favored the
appearance of a p-p38 higher molecular weight band indicative of
p38 hyperphosphorylation, indicating a similar regulation of PKD
and p38 by DUSP1.
Ischemic stroke causes neuronal inactivation of PKD. To
investigate neuronal PKD inactivation in in vivo excitotoxicity,
we examined samples from cerebral ischemia. First we used a
mouse model of transient cerebral ischemia that consisted in the
occlusion of the middle cerebral artery (MCAO) for 1 h followed
by 24 h reperfusion42. Hypochromatic Nissl staining marked
neuronal injury in the ischemic brain, distinguishing the ischemic
core at the striatum (Fig. 2a). Consistent with our in vitro results,
immunofluorescence analyses of brain sections showed peri-
nuclear and nuclear dotted staining of active PKD in neurons
(NeuN+) in the striatum from sham-operated mice that was
absent in the ischemic core at the equivalent region from MCAO-
operated animals (Fig. 2b). In the penumbra area, a high number
Fig. 1 PKD activity regulation in an in vitro model of NMDA-induced excitotoxicity. a Scheme showing activatory and autophosphorylation sites and
domains in PKD1. b p-PKD(S916), p-PKD(S744/S748), PKD, p-DAPK(S308), DAPK, and Spectrin immunoblot analysis of primary mature cortical neurons
stimulated with NMDA (50 μM) plus glycine (10 μM) (referred hereafter as NMDA) for various periods of time. Spectrin full-length (FL) and calpain-
breakdown products (BDPs) are shown. (Right panel) Quantification of immunoblot signals of p-PKD(S916) relative to total PKD and the loading control
neural-specific enolase (NSE). Each time point, p-PKD(S916) value was represented as fold increase relative to control untreated cultures (n= 5
independent experiments). c, d PKD, p-PKD(S916), and Spectrin immunoblot analysis of neurons pretreated for 1 h with the GluN2B-specific inhibitor
ifenprodil (IFN; 10 μM) or the NMDAR antagonist DL-AP5 (200 μM), and stimulated with NMDA for 5 min (c) or 1 h (d) (n= 3 independent experiments).
e Neurons were stimulated with NMDA as above for 5 min or 1 h. PKD1-Y93 phosphorylation after 5 min of NMDA treatment was detected following
immunoprecipitation and immunoblotting with a novel phosphospecific monoclonal antibody. Short and long exposure images of p-PKD(S916) and PKD
are included. f PKD, p-PKD(S916), and NSE (loading control) immunoblot analysis of neurons pre-incubated for 1 h with the PKC-δ inhibitor Rottlerin (5
μM) or the Src inhibitor SU6656 (5 μM) and treated with NMDA for 5 min (n= 3 independent experiments). g Neurons were exposed for 1 h to okadaic
acid (OA; 500 nM), to inhibit serine/threonine phosphatase PP1, or pervanadate (PV; 1 mM), to inhibit tyrosine phosphatases, and then stimulated with
NMDA for 1 h. Levels, processing or phosphorylation of PKD, p38, STEP, or DUSP1 were determined by immunoblot analysis (n= 3 independent
experiments). h Neurons transduced with lentivirus encoding shC, shDUSP1, or shSTEP were treated with NMDA as indicated. Dusp1 or Step silencing and
their effect on PKD inactivation in response to excitotoxicity was analyzed by immunoblotting. i Quantification of immunoblot signal of p-PKD(S916) higher
molecular weight band in h relative to total PKD and NSE, represented as fold increase relative to untreated cultures transduced with shC is shown as
mean ± s.e.m. (n= 3 independent experiments). *P< 0.05, **P< 0.01; n.s. not significant. two-tailed unpaired Student's t test. b–h Representative
immunoblots are shown
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of neurons had lost p-Ser916 signal compared to the same cortical
region in a sham-operated brain (Fig. 2c). This result was
reproduced in animals after MCAO for 1 h and a shorter post-
ischemic time of 5 h (Supplementary Fig. 4). We further exam-
ined the potential relevance of PKD inactivation in human brain
tissue from control donors and ischemic stroke patients (Sup-
plementary Table 1). While NeuN+ cells in control cortices
showed p-Ser916 immunostaining, cortices of stroke patients
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A critical role for PKD1 in neuronal survival. Next, we inves-
tigated whether PKD inhibition could mediate neuronal death.
A dose–response and a time-course treatment of cortical neu-
rons with the PKD-specific pharmacological inhibitor
CRT0066101 (CRT)43 showed that 10 µM CRT decreased PKD
basal activity and abrogated NMDA-induced activatory
response (Supplementary Fig. 5a–c). To examine the effect of
this inhibitor on neuronal death, we treated cortical cultures
with CRT alone or in combination with NMDA for 4 h and
quantified neurons (MAP2+) bearing condensed nuclei as
marker of neuronal damage. CRT alone elevated the number of
neurons showing nuclear condensation and increased NMDA-
induced nuclear condensation (Fig. 3a). MTT viability assays
showed similar results, where preincubation with CRT
decreased neuronal survival both in basal and excitotoxic con-
ditions (77 ± 6.2% vs. 100% of viability in control cells and 36±
4.8% vs. 48 ± 1.9% viable neurons in NMDA-treated cultures)
(Fig. 3b). No major changes were obtained at lower CRT doses,
except for a small decrease in basal neuronal survival at 5 µM
(Supplementary Fig. 5d).
To complete these studies, we transduced primary cortical
neurons with lentiviral particles encoding two Prkd1-specific
shRNA (shPKD1a and shPKD1b). Once confirmed
PKD1 silencing (Fig. 3c), we counted living MAP+ neurons and
found that Prkd1 knockdown decreased nearly 70% the number
of viable neurons (Fig. 3d). MTT assays showed that interference
of Prkd1 decreased neuronal viability in basal conditions and after
NMDA-induced excitotoxicity (Fig. 3e).
We next investigated the contribution of PKD1 to neuronal
survival in vivo. We generated mice with specific deletion of
Prkd1 in CaMKIIα-expressing neurons (PKD1 KO) by crossing
Prkd1-floxed mice44 (PKD1floxed) with mice expressing Cre under
neuronal CaMKIIα promoter (CaMKIIα-Cre mice) (Supplemen-
tary Fig. 6a). We confirmed Cre expression, efficient recombina-
tion in the Prkd1 locus and specific decrease of Prkd1 messenger
RNA (mRNA) in the cerebral cortex of these mice (Supplemen-
tary Fig. 6b, c). Primary cortical neurons cultured from PKD1 KO
mice showed lack of PKD1 protein compared to their control
PKD1floxed littermates (Supplementary Fig. 6d). DAB immuno-
histochemistry of PKD1 KO cerebral cortex showed almost a
complete disappearance of PKD antibody specific signal and a
substantial decrease in p-Ser916 content (Fig. 3f). Together with
results from PKD1 shRNA and immunoblot analysis with these
antibodies (Supplementary Fig. 1a), these data strongly suggest
that the remaining p-Ser916 signal might correspond to PKD2.
Nissl staining, as well as NeuN immunofluorescence did not show
noticeable differences between PKD1floxed and PKD1 KO animals
(Supplementary Fig. 6e, f). In addition, these animals did not
present macroscopic differences in their cerebrovascular anatomy
(Supplementary Fig. 6g). However, after experimental stroke by
MCAO, PKD1 KO suffered increased neuronal injury compared
to PKD1floxed animals, as determined by Nissl staining and T2-
weighted magnetic resonance imaging (MRI) (Fig. 3g). Our
results suggest that although there is no neuronal loss in PKD1
KO mice, their neurons are more sensitive to excitotoxicity and
oxidative stress damage. To test this notion, we first determined
ROS levels in PKD1 KO vs. PKD1floxed cultured cortical neurons
untreated or treated with NMDA (Fig. 3h; Supplementary
Fig. 6h). Although confocal microscopy images evidenced slight
ROS increases in untreated PKD1 KO neurons (Supplementary
Fig. 6h), flow cytometry quantification analysis showed that
differences between the two genotypes only reached significance
under excitotoxic conditions, where PKD1 KO contained higher
ROS amounts (Fig. 3h). We used MDA, a marker for lipid
oxidation by oxidative stress, to analyze the effects of oxidative
stress in PKD1floxed and PKD1 KO brain after sham or MCAO
surgery. Importantly, immunofluorescence and quantitative
analyses of brain sections showed substantially higher MDA
staining in neurons (NeuN+) of sham-operated PKD1 KO
compared to PKD1floxed mice (Fig. 3i). Cerebral ischemia
increased MDA labeling in both genotypes but levels in PKD1
KO registered a robust three-fold increase over those in
PKD1floxed brain (Fig. 3i).
Regulation of IKK/NF-κB pathway during excitotoxicity. The
inactivation of PKD by excitotoxicity led us to hypothesize that
the PKD1/IKK/NF-κB pathway may be constitutively active in
neurons and that NMDA-induced excitotoxicity and neuronal
death could be the consequence of the shut-off of this signaling
cascade. The NF-κB transcription factor, formed in neurons
mainly by the p65–p50 dimer45, is sequestered in the cytosol
through its binding to IκBα, which undergoes proteasomal
degradation after IKK phosphorylation46. Therefore, fluctuations
in IKK activity are usually translated into changes in the nuclear-
cytosolic localization and transcriptional activity of NF-κB46. To
challenge our hypothesis, we analyzed IKK activity during exci-
totoxicity finding a decrease in p-Ser176/177 signal indicative of
its inactivation after 1 h of NMDAR overstimulation (Fig. 4a).
Longer incubations with NMDA produced a stronger decrease in
p-IKK levels paralleled by an increase in IκBα (Supplementary
Fig. 7a).
We examined the localization of NF-κB p65 (referred as NF-
κB) in cultured neurons observing that nearly 100% of MAP2+
neurons presented NF-κB in the nucleus (Fig. 4b) and that
NMDA treatment induced significant decreases in NF-κB nuclear
signal (Fig. 4b, see quantification in the right panel). NF-κB
activity was also explored detecting its Ser536 phosphorylation by
immunofluorescence. Phosphorylated NF-κB signal constitutively
localized at neuronal nuclei and underwent a strong loss after 2 h
of NMDA addition (Supplementary Fig. 7b).
To further confirm excitotoxic changes on NF-κB transcrip-
tional activity in neurons, we performed luciferase assays and
observed a significant luciferase activity decrease in NMDA-
treated neurons (Fig. 4c). Finally, using RT-qPCR we also
Fig. 2 Neuronal inactivation of PKD in mouse and human ischemic brain. a–c Wild-type mice were sham-operated or subjected to 60min of MCAO and
killed 24 h after reperfusion. (a, left panels) Representative images of coronal brain sections stained with Nissl are shown. The ischemic core in the striatum
(S) and in the adjacent cortex (C) corresponding to the penumbra area and the equivalent areas in sham-operated animal are depicted. b, c Representative
confocal microscopy images showing predominant localization of p-PKD(S916) staining in NeuN+ cells in brain from sham-operated animals, the absence
of active kinase, and NeuN staining at the striatum (b) or the decrease in p-PKD(S916) signal on NeuN+ cells at the cortical penumbra area in ischemic
brain (c, left panels). (c, right panel) Percentage of NeuN+ cells containing p-PKD(S916) staining in penumbra zone of MCAO-operated mice compared to
the equivalent cortical region of sham-operated animals (n= 100 neurons; n= 3 sections per animal, n= 3 animals per condition). d Decreased number of
neurons with p-PKD(S916) staining in postmortem human ischemic stroke samples compared to that from control subjects. Representative confocal
microscopy images showing predominant localization of p-PKD(S916) staining in NeuN+ cells in samples C-1 and S-2 are shown (Supplementary Table 1).
(Right panel) Percentage of neurons bearing active p-PKD (n= 30–50 neurons per section; n= 3 individuals per condition). c, d Zoom images from boxed
regions are also shown. For quantifications, mean± s.e.m. were derived from the indicated number of samples and analyzed with two-tailed unpaired
Student's t test. ***P< 0.001
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02322-5
6 NATURE COMMUNICATIONS |  (2017) 8:2275 |DOI: 10.1038/s41467-017-02322-5 |www.nature.com/naturecommunications
determined that mRNA levels of Sod2 and those of Bdnf, a
prosurvival neurotrophin whose transcription can be regulated by
NF-κB47, were downregulated by excitotoxicity (Fig. 4d).
Together, these data indicate that neurons present a substantial
basal NF-κB activity that is downregulated under excitotoxic
conditions.
To determine the relevance of this pathway in vivo, we
examined neuronal nuclear NF-κB localization in MCAO-
operated mice. According to our in vitro data, NF-κB was
present in the nucleus of almost all NeuN+ cells in the striatum
and cortex from sham-operated mice. However, ischemia
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striatal ischemic core (Supplementary Fig. 7c) and a substantial
nuclear loss in the cortical penumbra area (Fig. 4e). Importantly,
we obtained similar results in human postmortem brain samples
from ischemic stroke patients, where NF-κB was absent in
neuronal nuclei from ischemic stroke patients but presented
nuclear localization in control subjects (Fig. 4f).
Collectively, our results strongly suggest that the PKD1/IKK/
NF-κB pathway is constitutively “on” in healthy neurons and
suffers an early and sustained “shut-off” in human brain after
ischemic stroke and in experimental models of excitotoxicity and
brain ischemia.
PKD1 protects neurons through the IKK/NF-κB/SOD2 path-
way. Next we assessed the effect of a dephosphorylation-resistant
and constitutively active PKD1 mutant in neuroprotection from
excitotoxicity. To engineer this mutant, we substituted the four
critical residues involved in PKD activation (Tyr93, Tyr469,
Ser744, and Ser748) (Fig. 1a) by glutamic acid, to mimic their
phosphorylation state. In vitro kinase assays confirmed its con-
stitutive activity (Supplementary Fig. 8a). We fused this quad-
ruple mutant to GFP in a lentiviral vector (PKD1-Ca) bearing
human synapsin neurospecific promoter (SYNpr) (Fig. 5a). GFP
alone expressed under the same promoter was used as control
lentivirus. Neurons transduced with PKD1-Ca lentivirus expres-
sed high amounts of active PKD1 (Fig. 5b) and presented sub-
stantial increases in IKK activity (Fig. 5b) and a highly significant
induction of SOD2 levels relative to GFP-transduced cells
(Fig. 5b). Accordingly, NMDA-induced ROS production in
PKD1-Ca neurons was very low (111± 10.4%) and similar to that
of untreated GFP neurons, compared to NMDA-treated GFP
neurons (148± 7.8%) (Fig. 5c).
Analysis of MAP2 staining confirmed that PKD1 activation
confers neuroprotection against NMDA-induced excitotoxicity
(Fig. 5d). Most GFP neurons were not viable after 4 h of NMDA
treatment, and presented disorganized MAP2 staining, whereas a
prominent number of PKD1-Ca neurons remained viable at this
time (Fig. 5d). Importantly, a high number of PKD1-Ca neurons
survived even 24 h upon NMDA addition (50.4± 11%), when
almost all GFP neurons were dead (13.5± 3%) (Fig. 5d).
Furthermore, NF-κB remained in the nucleus of most PKD1-Ca
transduced neurons after 1 h of NMDA treatment in contrast to
its cytosolic translocation in a high proportion of GFP neurons
(Fig. 5e). The possibility that PKD1-Ca increased neuronal
survival by inhibiting Ca2+ influx evoked by NMDARs
overactivation was ruled out after performing Ca2+ imaging
analysis (Supplementary Fig. 8b).
To demonstrate that increases in SOD2 conferred by PKD1-Ca
were dependent on IKK/NF-κB pathway, we treated transduced
neurons with the IKK inhibitor SC-514. IKK inhibition decreased
SOD2 levels in PKD1-Ca transduced cells (Fig. 5f, left and
medium panels). The action of SC-514 was confirmed by the
accumulation of IκBα (Fig. 5f, left and right panels). We finally
examined the effect that pharmacological inhibition of IKK had
on PKD1-mediated neuroprotection. MTT assays showed that
IKK inhibition reduced the resistance of PKD1-Ca neurons to
excitotoxic death: 98.6± 0.6% of PKD1-Ca-transduced neurons
survived after 4 h of NMDA treatment, whereas only a 73.79±
0.02% of them were alive after combining SC-514 and NMDA
treatments (Fig. 5g). Together, our results indicate that PKD1 is
neuroprotective against excitotoxic insults by busting the IKK/
NF-κB/SOD2 axis and contributing to ROS detoxification.
PKD1 protects against kainic acid-induced excitotoxicity. To
investigate PKD1 neuroprotection in vivo, we selected a model of
KA-induced neurodegeneration that elicits selective excitotoxic
neuronal death particularly in limbic structures (i.e., hippocampal
CA1 and CA3 regions) in the rat and mouse brain3.
We first observed in cultured primary neurons that similarly to
NMDA, excitotoxic concentrations of KA produced a transient
activation of PKD followed by inactivation (Fig. 6a). MTT assays
and MAP2 staining showed that KA reduced neuronal viability,
and that KA-induced neuronal death was mediated by KA
receptors (KARs) (Supplementary Fig. 9a–c). Importantly, KA
also provoked the exit of NF-κB from neuronal nuclei (Fig. 6b).
To confirm that PKD and NF-κB were inactivated in neurons
during in vivo KA-induced excitotoxicity, we examined the CA1
hippocampal area in control adult rats that received an
intraperitoneal injection of saline or KA. CA1 neurons from
control saline-injected animals presented active PKD and nuclear
NF-κB staining (Fig. 6c). In line with our observations after
cerebral ischemia, KA treatment induced condensation of
neuronal nuclei in the damaged CA1 area and a marked decrease
of NeuN, p-PKD and nuclear NF-κB content in neurons (Fig. 6c),
while p-PKD signal emerged in a different cell population.
Altogether, these results strongly suggest that excitotoxicity
induced by NMDARs or KARs overstimulation triggers similar
molecular mechanisms that result in PKD and NF-κB neuronal
inactivation preceding their death.
Fig. 3 Elimination of PKD1 activity enhances neuronal death in vitro and in vivo. a (Left panels) Representative confocal microscopy images of DAPI and
MAP2 staining of primary neurons treated for 1 h with CRT (10 μM) or vehicle (DMSO) followed by 4 h of NMDA. (Right panel) Percentage of these
neurons bearing condensed nuclei relative to neurons treated 4 h with NMDA (n= 120–150 neurons per condition; n= 3 independent experiments). b
Neuronal viability measured by MTT assays after treatment with CRT and NMDA as above, relative to untreated neurons (triplicates per condition, n= 5
independent experiments). c PKD and NSE (loading control) immunoblot analysis and d confocal microscope images of MAP2 and DAPI staining of cortical
neurons transduced with lentivirus encoding shC, shPKD1a, or shPKD1b. (d, right panel) Quantification of MAP2+ cells relative to shC-transduced cultures
(n= 70–200 neurons per condition; n= 3 independent experiments). e shC- or shPKD1b-transduced neuronal cultures were treated with NMDA for the
indicated times and viability was evaluated by MTT assays. Data are expressed relative to shC-transduced untreated neurons (triplicates per condition, n=
4 independent experiments). f PKD (left panels) and p-PKD(S916) (right panels) DAB immunostaining in cortex sections from PKD1floxed and PKD1 KO
mice. Representative images and zoom-boxed regions are also shown. g PKD1floxed and PKD1 KO mice were subjected to 60min of MCAO. Representative
images of (left panels) Nissl-stained coronal brain sections and (middle panels) coronal T2-weighted MRI images obtained from the same animals 24 h
after reperfusion. (Right panel) quantification of the infarct volume (mm3) in PKD1 KO (n= 10) and PKD1floxed mice (n= 7). Yellow dotted lines mark the
ischemia boundary. h Flow cytometry analysis of DHE staining in PKD1floxed and PKD1 KO cultured neurons unstimulated or after NMDARs overstimulation
for 1 h. Data are shown relative to untreated PKD1floxed neurons (n= 4 independent experiments). i Representative confocal microscopy images of MDA-,
NeuN-, and DAPI-stained cortical penumbra area from MCAO-operated mice and the equivalent cortical region of sham-operated animals in PKD1floxed
and PKD1 KO. (i, right panel) Percentage of NeuN+ cells containing MDA staining in penumbra zone of MCAO-operated mice (I) compared to the
equivalent cortical region of sham-operated animals (S) expressed relative to that of sham PKD1floxed (n= 150 neurons; n= 2 sections per animal, n= 3
animals per condition). For quantifications, mean± s.e.m. were derived from the indicated number of independent experiments. *P< 0.05, **P< 0.01, ***P
< 0.001; two-tailed unpaired Student's t test (a–f, h–i) and two-tailed unpaired Student's t test with Welch's correction (g)
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Next we assayed the effects of PKD1-Ca neurospecific
expression in neuroprotection from KA-induced death. This
was initially performed in vitro, analyzing neuronal cultures
transduced with GFP or PKD1-Ca lentivirus and treated with KA
for 48 h. We found almost complete lack of neuronal death in
PKD1-Ca cultures, in contrast to the extensive neuronal death
provoked by KA in GFP neurons, where nearly a 60% of the
neuronal population died (Fig. 6d).
Finally, to investigate PKD1 neuroprotection in vivo, we
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the right and left CA1 region of the rat hippocampus,
respectively, previous to KA administration (Fig. 7a). In saline-
injected animals, GFP+ neurons in CA1 presented nuclear
localization of NF-κB independently of whether they were
transduced (GFP+) or not (Fig. 7b, see details in zoom images).
By contrast, after KA injection there was a clear damage and loss
of transduced neurons in the right CA1 GFP-transduced side, as
evidenced by spare fragmented GFP staining and condensation of
NeuN-stained nuclei (Fig. 7c). Remaining neurons looked
damaged, presented aberrant shape and smaller compacted
nuclei, and sparse nuclear NF-κB staining (Fig. 7c). However,
neurons in the left CA1 side appeared healthier, not only those
transduced with PKD1-Ca (GFP+), but also non-transduced
neurons surrounding them, many of which still contained NF-κB
in their nuclei (Fig. 7c).
To further support PKD1-mediated neuroprotection using
quantitative approaches, we measured hippocampal CA1 neuro-
nal degeneration by FluoroJade B staining. We found a highly
significant decrease in KA-induced neuronal death (represented
as the % of FluoroJade B staining), in the left CA1 side transduced
with PKD1-Ca compared with the right side GFP-transduced
(12.65± 3% PKD1-Ca vs. 28.19± 3.6% GFP) (Fig. 7d).
Discussion
Neurons are considered to be highly sensitive to oxidative stress
damage48, but precisely because they are post-mitotic cells that
survive for many years, they must have well developed natural
defences against oxidative stress. Here we have discovered that a
constitutively active neuronal PKD1/IKK/NF-κB/SOD2 oxidative
stress-detoxifying cascade is turned off during excitotoxic neu-
rodegeneration, depleting neurons of this antioxidant natural
defence and greatly hampering their survival (Fig. 7e). Our results
support the notion that PKD1 enhances IKK activity, NF-κB
nuclear localization and SOD2 expression, and decreases ROS
production in neurons under oxidative stress conditions.
Excitotoxic damage accumulated along aging or enhanced by
acute or chronic neurodegenerative disorders could gradually
deteriorate this antioxidant pathway. PKD1 activity withdrawal,
accompanied by NF-κB nuclear exit, and subsequent decrease in
SOD2 levels would decrease the threshold of the amount of ROS
neurons can cope with. ROS elimination through the action of
SOD2 would be severely hampered (Fig. 7e). Cultured Prkd1−/−
immortalized fibroblasts showed increased ROS production due
to a decrease in the threshold of mitochondrial depolarization49,
suggesting the possibility that this mechanism may also con-
tribute to increase ROS levels in neurons. The accumulation of
ROS in PKD1-deficient neurons, by lack of clearance or by
overproduction, may increase oxidative damage and neuronal
vulnerability and death. Accordingly, we observed increased
MDA labeling in the brain of PKD1 KO mice relative to
PKD1floxed littermates.
This PKD–ROS detoxification pathway was identified in a
pancreatic cancer mouse model and in cancer cell lines, having as
a result the promotion of precancerous lesions50 and the poten-
tiation of cellular survival12, respectively. Contrary to tumor cells,
this activation is not sustained in neurons, as demonstrated by
decreases in PKD and IKK activities and in NF-κB nuclear
localization and activity preceding excitotoxic neuronal death. A
transient activation of PKD was found also in dopaminergic cells
treated in vitro with hydrogen peroxide, but mechanisms of
inactivation or downstream signaling cascades were not
explored51. Here, we identify for the first time a molecular
mechanism involved in PKD dephosphorylation downstream
overstimulation of endogenous NMDARs. This inactivation
mechanism depends on PP1 and DUSP1, two PPs whose activ-
ities are increased under excitotoxicity35, 40 (Fig. 7e).
A key point in PKD sustained activation and survival of cancer
cells under oxidative stress might relay on their deficiencies in the
control of PKD inactivation mechanisms achieved by PPs. For
instance, DUSP1 levels inversely correlate with NF-κB activity
and their malignancy grade in prostate cancer52. In this context,
while specific inhibition of PKD1 could provide clear therapeutic
advantages in cancer, our results indicate that this type of treat-
ments could represent a high risk for associated neurodegenera-
tion. Conversely, the future development and therapeutic
application of PKD activators for neuroprotection should be
exquisitely targeted to neurons to unequivocally avoid undesired
pro-survival effects on other cell types.
Regarding the existing controversy on NF-κB contribution to
neuroprotection and neurotoxicity18, our data highlight the
importance of this pathway for neuronal survival. This study
strengthens the need to perform careful cell-type specific analysis
of this and other signaling pathways in complex tissues, identi-
fying pathological changes occurring in cells subpopulations.
Revisiting published results obtained from tissue homogenates is
essential before drawing final conclusions of the contribution of a
specific pathway to disease.
In summary, this study constitutes the first one demonstrating
that PKD1 confers neuroprotection against the oxidative stress
produced after overstimulation of endogenous glutamate recep-
tors by triggering antioxidant defences and promoting neuronal
survival in an excitotoxic environment. On the basis of our
Fig. 4 Downregulation of IKK/NF-κB pathway in neurons during in vitro and in vivo excitotoxicity parallels PKD inactivation. a (Top panel) Representative
p-PKD(S916), PKD, p-IKK(S176/S177), IKK, and NSE (loading control) immunoblot analysis of cortical neurons stimulated with NMDA for the indicated
times and (bottom panel) quantification of IKK activity after normalizing p-IKK(Ser176/177) densitometric values with those of total IKK and NSE. For each
time point, p-IKK values were represented as fold increase relative to untreated cultures (n= 5 independent experiments). b Representative images of
MAP2, NF-κB, and DAPI staining of cortical neurons treated with NMDA for 1 or 2 h. Zoom-boxed regions are also shown. (Right panel) Number of
neurons bearing NF-κB nuclear staining before and after NMDARs overstimulation relative to untreated cells (n= 50–100 neurons per condition; n= 3
independent experiments). c Cortical neurons were transfected with tk-Luc and (NF-κB)3-tk-Luc reporter vectors. Luciferase activity was measured after
48 h in unstimulated neurons or stimulated with NMDA 3 h. Firefly luciferase activity was normalized to that of Renilla luciferase activity in each sample,
and expressed relative to that of tk-Luc control (n= 3 independent experiments). d RT-qPCR analysis of Sod2 and Bdnf mRNA levels in cortical neurons
untreated or treated with NMDA for 2 h shown relative to untreated neurons (n= 3 independent experiments). e Representative confocal images of NeuN,
NF-κB, and DAPI staining in cortex of sham- or MCAO-operated animals. Zoom-boxed regions are also shown. (Right panel) Percentage of NF-κB nuclear
staining in the penumbra cortical zone from MCAO brain relative to the equivalent region from sham-operated animals (n= 100 neurons, n= 3 sections
per animal, n= 3 animals per condition). f Representative images of maximal projections and orthogonal views of a z-stack for double NF-κB/NeuN and
NF-κB/DAPI staining of postmortem brain samples from control subjects (left panels) and ischemic stroke patients (medium panels). Images correspond
to samples C-1 and S-2 (Supplementary Table 1). (Right panel) Percentage of neurons bearing nuclear NF-κB (n= 30–50 neurons per section; n= 3
individuals per condition). For quantifications, mean± s.e.m. were derived from the indicated number of independent experiments or samples and analyzed
with two-tailed unpaired Student's t test. *P< 0.05, **P< 0.01, ***P< 0.001
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findings, we propose that the development of a broad therapeutic
strategy based on preserving PKD1 activity in neurons might be
beneficial to slow-down neuronal loss taking place during aging
or in a broad range of acute and chronic neurodegenerative
diseases by enhancing neuronal natural antioxidant defences.
Methods
Materials and chemicals. NMDA, glycine, cytosine β-D-arabinofuranoside
(AraC), poly-L-lysine, L-laminin, IFN, [3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide] (MTT), Rottlerin, SU6656, EGTA, Z-VAD-FMK, dime-
thylsulfoxide (DMSO), and sodium orthovanadate (Pervanadate, PV) were from
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A23187, and SC-514 were from Calbiochem (UK). Okadaic acid (OA), 3-(4-
chlorophenyl)-1-(1,1-dimethylethyl) 1-H-pyrazolo[3,4-d] pyrimidin-4-amine
(PP2), DL-2-amino-5-phosphonopentanoic acid (DL-AP5), and 6-cyano-7-nitro-
quinoxaline-2, 3-dione (CNQX) were from Tocris Bioscience (Bristol, UK).
Cyclosporine A (CsA) and FK-506 were from Sandoz (Vienna, Austria) and LC
Laboratories (Wobum, MA, USA), respectively. KA was from Abcam (Cambridge,
UK). CRT0066101 was kindly provided by Cancer Research UK Transfer Tech-
nology Department (London, UK).
Commercial antibodies. Rabbit polyclonal antibodies were: PKD, phospho-PKD-
S916 and phospho-PKD-S744/748, p38 and phospho-p38-T180/Y182, IKKβ, NF-κB
phospho-p65-S536 (Cell Signaling Technology, Beverly, MA, USA); phospho-S176/
177 IKKα/β (Biorbyt, San Francisco, CA, USA); NSE (ICN Biomedicals; Costa
Mesa, CA, USA); total and phospho-S308 DAPK (Sigma-Aldrich); Superoxide
dismutase 2 (SOD2), microtubule-associated protein 2 (MAP2), PKD/PKC mu
(phospho-Y463) (Abcam); GFP (ThermoFisher Scientific Invitrogen, Waltham,
MA, USA); NF-κB p65, IκBα, DUSP1 (Santa Cruz Biotechnology, CA, USA).
Mouse monoclonals were: NeuN, Spectrin (Millipore Corporation, Billerica, MA,
USA), STEP (Novus Biologicals, Littleton, CO, USA), MDA (Jaica, Japan). Detailed
information about all the above-mentioned antibodies and dilutions used for the
different applications is given in Supplementary Table 2. Horseradish peroxidase-
conjugated anti-rabbit and anti-mouse secondary antibodies were from Santa Cruz
Biotechnology and Alexa-Fluor-488, -555, and -647 conjugated antibodies were
from ThermoFisher Scientific.
Generation of phosphospecific PKD1 p-Tyr93 monoclonal antibody. Eight-
week-old female BALB/c mice produced at the animal care facility at Centro
Nacional de Biotecnología (CNB, CSIC, Madrid, Spain) were immunized sub-
cutaneously with a KLH-conjugated synthetic phosphopeptide corresponding to
amino acids 88–98 of human PKD1 (homologous to mouse amino acids 86–96,
containing Y93) (KFPE*CGFpYGMY), where *C refers to acetamidomethyl (Acm)
cysteine. Spleen cells from these mice were then fused with P3X63Ag8.653 (ATCC
CRL-1580, mycoplasma free) mouse myeloma cells. Hybridoma supernatants were
screened for the presence of phosphospecific antibodies by enzyme-linked immu-
nosorbent assay (ELISA) using phosphopeptide and nonphosphopeptide bound to
the plate as described previously53. Selected hybridomas, producing antibodies that
reacted specifically with the phosphopeptide, were cloned twice by limiting dilution.
We selected a hybridoma whose supernatant reacted specifically with the phos-
phopeptide and recognized specifically PKD1 phosphorylated at Tyr93 in rat
neuronal lysates after pervanadate (PV; 1 mM) or H2O2 (1 mM) stimulation
(Supplementary Fig. 2). This antibody was named: Phospho-PKD1 (Tyr93)
monoclonal antibody (clone 6E8). Its isotype was determined by ELISA as IgG2b.
Experimental animals. Mice with neuronal conditional deletion of Prkd1 (PKD1
KO mice) in a C57BL/6 background were obtained after crossing Prkd1loxP/loxP
animals (PKD1floxed)44 with CaMKIIα-Cre mice (stock number 005359, The
Jackson Laboratory, Bar Harbor, ME, USA). Only male PKD1floxed and PKD1-KO
mice were used and littermates were employed in each independent experiment for
comparison purposes. Genotyping and recombination analysis in mouse brain
cortex was performed by PCR using specific pairs of primers44. Presence of Cre and
flox cassettes was also tested.
Wild-type C57BL/6, C57BL/6 PKD1floxed, and PKD1-KO embryos of 17 days
and Wistar rat embryos of 19 days were produced at the animal care facility at
Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBm, CSIC-UAM, Madrid,
Spain). Adult male Wistar rats (8–10 weeks old) weighing 250–280 g were used for
KA treatment. Rats were obtained from the animal care facility at Centro de
Biología Molecular “Severo Ochoa” (CBMSO, CSIC-UAM, Madrid, Spain).
All animals were maintained under 12-h light/12-h dark cycle and with access
to food and water ad libitum. Procedures involving animals had been approved by
institutional (Consejo Superior de Investigaciones Científicas and Universidad
Autónoma de Madrid) and local (Instituto de Investigaciones Biomédicas “Alberto
Sols”, Centro de Biología Molecular “Severo Ochoa”, and Centro Nacional de
Biotecnología) Ethical Committees, and were conformed to the appropriate
national legislations (RD 53/2013) and the guidelines of the European Commission
for the accommodation and care of laboratory animals (revised in Appendix A of
the Council of Europe Convention ETS123).
Transient cerebral ischemia mouse model. Transient focal ischemia was pro-
duced in 4-month-old male C57Bl/6 mice (30 g body weight) by intraluminal
occlusion of the middle cerebral artery for 60 min followed by reperfusion (pro-
cedure referred as “MCAO”), as described42. Briefly, mice were anesthetized with
2.5% isofluorane before a 1.1-cm length of 7-0 monofilament silk suture was
introduced into the common carotid artery up to the level where the middle cer-
ebral artery branches out; animals were sutured then and placed in their cages with
free access to water and food. After 60 min, animals were reanesthetized and the
filament was removed to allow reperfusion. Anesthesia was discontinued again, and
the animals were allowed to recover. Mice were reanesthetized and examined 5 h or
1 day after reperfusion with T2W MRI, at the Magnetic Resonance facility
(Instituto de Investigaciones Biomédicas “Alberto Sols”), to evaluate the extent of
edema and brain infarction. To calculate the total infarct volume in mm3, the
infarct area was measured in all the series of images obtained in MRI-T2W for each
animal. MRI-ADC images were also acquired after 2 h of reperfusion in the groups
of animals subjected to the short MCAO procedure to identify and quantify edema
within the ischemic hemisphere.
Human brain samples. Brain samples from ischemic stroke patients (n = 4), and
control subjects (n = 3) and postmortem intervals between 3 and 15 h were
obtained from the Institute of Neuropathology Brain Bank (for details see Sup-
plementary Table 1) following Spanish legislation and local Ethics Committee
guidelines and processed as described54. Briefly, one brain hemisphere was
immediately cut in coronal sections (1 cm-thick) and selected areas were rapidly
dissected, frozen over dry ice on metal plates, placed in individual plastic bags, and
stored at −80 °C for their use in biochemical studies. The other hemisphere was
used for morphological studies after fixation by immersion in 4% buffered formalin
for 3 weeks. Samples of selected regions of the brain were embedded in paraffin and
15-μm sections were stained for neuropathological studies with hematoxylin and
eosin, periodic acid-Schiff (PAS) and Klüver–Barrera, or processed for immuno-
histochemistry and immunofluorescence (see “Immunohistochemistry of rat,
mouse, and human brain samples” section and details for antibodies and dilutions
used in Supplementary Table 2). All participants gave their written consent, and
the study was approved by the local Ethics Committee (Bellvitge University
Hospital-Bellvitge Biomedical Research Institute, IDIBELL), following the ethical
standards recommended by the Helsinki Declaration.
Stereotaxic intracerebral injection of lentiviral particles. Male rats 8–10 weeks
old were anesthetized with isoflurane and placed in a stereotaxic frame. Coordi-
nates (mm) relative to bregma in the antero-posterior (AP), medio-lateral (ML),
and dorso-ventral (DV) axes were as follows: CA1 (−4 AP; ±2.40ML and −2.5
DV). GFP and PKD1-Ca lentiviral particles were injected in CA1 hippocampal
regions at the right and left hemisphere, respectively, of the same animal using glass
Fig. 5 Phosphatase-resistant active PKD1 enhances IKK/NF-κB/SOD2 pathway and reduces excitotoxicity-induced ROS levels and neuronal death. a
Scheme of the lentiviral vector used for neuronal expression of a phosphatase-resistant active PKD1 mutant (PKD1-Ca), where glutamic acids substitute the
four activatory residues (Tyr93, Tyr469, Ser744, and Ser748). GFP alone or fused to PKD1-Ca was cloned under the neurospecific human synapsin
promoter (SYNpr). b Immunoblot of PKD and IKK activities and SOD2 levels from primary neurons transduced with GFP or PKD1-Ca lentivirus. Quantitative
analysis of (medium panel) p-IKK(S176/177) after normalization with total IKK and NSE, or (right panel) SOD2 after normalization with NSE, in GFP-
transduced neurons (n= 3 independent experiments). c ROS production in GFP- or PKD1-Ca-transduced neurons unstimulated or after NMDARs
overstimulation for 1 h determined by Cell Rox deep red reagent and FACs analysis, expressed relative to untreated GFP-transduced neurons (n= 4
independent experiments). d Representative images of GFP, MAP2, and DAPI signal of GFP- or PKD1-Ca-transduced neurons treated with NMDA for 4 or
24 h. Zoom-boxed regions are also shown. Transduced neurons were GFP+. (Right panel) Percentage of GFP+ surviving neurons (transduced with GFP or
PKD1-Ca) after 24 h NMDA treatment, relative to total GFP+ neurons in untreated conditions (n= 120–250 neurons per condition; n= 4 per group). e
Representative images of MAP2, NF-κB, and DAPI staining of GFP- or PKD1-Ca-transduced neurons treated with NMDA for 1 h. See inserts with zoom
images. (Right panel) Percentage of neurons bearing nuclear NF-κB before or after NMDARs overstimulation (n= 50–100 neurons per condition; n= 3
independent experiments). f GFP- or PKD1-Ca-transduced neurons were treated for 6 h with the IKK inhibitor SC-514 (10 μM) or with vehicle (DMSO).
Representative immunoblots with the indicated antibodies (left panel) and quantitative analysis of (middle panel) SOD2 and (right panel) IκBα levels
normalized to NSE. Data are expressed relative to control GFP+ neurons (n= 4 per group). g Neuronal viability was measured by MTT assays in GFP- or
PKD1-Ca-transduced cortical cultures treated for 6 h with SC-514 or vehicle (DMSO) followed by 4 h with NMDA. Data are expressed relative to untreated
neurons (triplicates per condition; n= 4 independent experiments). For quantifications, mean± s.e.m. were derived from the indicated number of
independent experiments. *P< 0.05, **P< 0.01, ***P< 0.001, n.s. not significant. two-tailed unpaired Student's t test
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Fig. 6 PKD1 mediates neuroprotection from in vitro KA-induced excitotoxicicity. a Primary cortical neurons were stimulated with excitotoxic concentrations
of KA (50 μM) for various periods of time and PKD activity and Spectrin processing were determined by immunoblotting. Representative immunoblots are
shown (n= 3 independent experiments). b Representative images of MAP2, NF-κB, and DAPI staining of neurons treated with KA for 4 h. Zoom-boxed
regions are also shown. (n= 3 independent experiments). c Brain slices from adult male Wistar rats treated with saline or KA (8.5 mg per kg, i.p.) were
stained with p-PKD(S916) or NF-κB in combination with NeuN and DAPI. Representative confocal microscopy images of the hippocampal CA1 region are
shown (n= 3 animals per conditions). d Representative images of GFP fluorescence and MAP2 and DAPI staining of primary cultured neurons transduced
with GFP or PKD1-Ca lentivirus and treated with KA for 48 h. Zoom-boxed regions are also shown. (Right panel) Neuronal survival was determined
counting the number of living GFP+ neurons 48 h after KA treatment and shown relative to the number of GFP+ neurons transduced with GFP or PKD1-Ca
in untreated conditions (n= 200–400 neurons per condition; n= 3 independent experiments). Data are expressed as mean + s.e.m. analyzed with two-
tailed unpaired Student's t test. *P< 0.05, ***P< 0.001
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micropipettes. A total volume of 2.5 μl per CA1 region of each viral suspension at a
concentration of 107–108 pfu per ml) was infused at 0.2 μl per min using an
automatic infusion pump.
Treatment with kainic acid. Twelve days after lentiviral CA1 intracerebral
injection, rats were treated with a single intraperitoneal (i.p.) dose of KA (8.5 mg
per Kg) or with an equivalent volume of 0.9% saline solution. To verify neuro-
toxicity induction by KA, behavioral observations were made during 3 h post
injection. All KA-treated animal displayed general limbic seizure activity. Seizures
were scored as previously described55. Three days after KA treatment, animals were
anesthetized and perfused for further immunohistochemistry analysis.
Primary culture and treatment of cortical neurons. Rat cortical neurons were
prepared from cerebral cortex of 19-day-old Wistar rat embryos as previously
described23, 24. Briefly, cerebral cortices were dissected and mechanically
dissociated in 4 ml of MEM culture medium (Eagle’s minimum medium, Ther-
moFisher Scientific Gibco), supplemented with 5% fetal bovine serum, 5% horse
serum, 22.2 mM glucose, 0.1 mM Glutamax-I (ThermoFisher Scientific Gibco),
penicillin (100 U per ml) and streptomycin (100 U per ml). Cells were plated at a
density of 2.5 × 105 cells per cm2 in the same medium in plates or coverslips
previously treated with poly-L-lysine (100 μg per ml) and laminin (4 μg per ml). At
day 7, cytosine β-D-arabinofuranoside (10 μM) was added to the culture and
maintained until the end of experiments to inhibit growth of glial cells. After
14 days in vitro (DIV), neurons were pretreated or treated for different time
periods as indicated with the following concentrations of compounds: 50 μM
NMDA and 10 μM glycine (combination referred as “NMDA” along the manu-
script), 200 μM DL-AP5, 10 μM IFN, 4 μM A23187, 2 mM EGTA, 25 μM Z-VAD-
FMK, 20 μM CNQX, 3.5 μM GFI, 5 μM Rottlerin, 5 μM PP2, 5 μM SU6656, 500
nM or 1 nM OA, 1 mM PV, 200 ng per ml FK506, 100 ng per ml CsA, 10 μM CRT,
20 μM SC-514, 50 μM KA, 1 mM H2O2. Excitotoxicity was induced in cortical
neurons by overstimulation of NMDARs with the co-agonists NMDA and glycine
20 μm
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or by overstimulation of KARs with KA. Unless otherwise stated, inhibitors were
added 1 h before NMDA treatment and remained in the culture media for the
duration of the experiment.
Cultures of mouse cortical neurons from E17 brain cortex of PKD1floxed and
PKD1-KO animals were prepared as previously described56. Briefly, tissue was
incubated in a 0.25% trypsin solution in Ca2+/Mg2+ free Hank’s buffered salt
solution (HBSS) and dissociated using fire polished Pasteur pipettes. Then neurons
were seeded at a density of 0.5 × 105 cells per cm2 on coverslips or dishes as above
in MEM complemented with 10% horse serum, 0.6% glucose, 0.1 mM Glutamax-I,
penicillin (100 U per ml), and streptomycin (100 U per ml), for 2 h until they
attached. Medium was then replaced by Neurobasal medium containing
B27 supplement and 2 mM Glutamax-I (ThermoFisher Scientific Gibco). Cytosine
β-D-arabinofuranoside (10 μM) was added to the culture at DIV3. Neurons were
maintained in the same original medium and used at DIV11. All cultures were
incubated at 37 °C in a humidified atmosphere containing 5% CO2.
Preparation of protein extracts, immunoprecipitation, and immunoblot ana-
lysis. Protein extracts from primary cultures were prepared in RIPA as previously
described23, 24. Briefly, cultured neurons were lysed in RIPA buffer (25 mM Tris-
HCl, pH 7.6, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM
NaCl) with protease and phosphatase inhibitors for 30 min at 4 °C. Lysates were
centrifuged for 30 min at 14,000 rpm at 4 °C, and resulting supernatant was con-
sidered the total lysate soluble fraction. For immunoprecipitation of PKD p-Tyr93,
1 mg of neuronal protein extracts was incubated with 50 μl of the p-Tyr93 hybri-
doma supernatant. After 4 h at 4 °C, immunocomplexes were bound to protein G
Sepharose for 1 h at 4 °C. Beads were washed four times with RIPA buffer before
solubilization in sample buffer. Equal amounts of total lysates or immunopreci-
pitates were resolved in SDS–PAGE and analyzed by immunoblot. Membranes
were incubated with different primary and secondary antibodies and immunor-
eactive bands were detected by ECL (PerkinElmer, Waltham, MA USA). Immu-
noblot images have been cropped for presentation. Full size images are presented in
Supplementary Figs. 10–15.
RNA isolation and reverse transcription-PCR and quantitative real-time PCR
analysis. Total RNA from the cortex of PKD1floxed and PKD1-KO mice was
isolated with RNAasy Mini Kit (Qiagen, The Netherlands), treated with RQ1
RNase-free DNase (1 U per μg RNA; Promega Corporation, Madison, WI), and
reverse-transcribed into complimentary DNA (cDNA), using oligo-dT extension
with Superscript II (Invitrogen, Carlsbad, CA). For PCR amplification, pairs of
primers specific for mouse Prkd1, Prkd2, and Prkd3 were used (Prkd1, forward
5′-GCCAAGGCCTTAAATGTGAA-3′, reverse 5′-GGAGCTTGTCGAGCTGAAT
C-3′; Prkd2, forward 5′-CTTGGATCTCCAGTCGCCGC-3′, reverse 5′-ACAGAA
CCACCTCCACCAGGTCA-3′; Prkd3, forward 5′-TGGTAATGTG CAGGGT-
CAAA-3′, reverse 5′-GGCTCCTCTGAGTCATCCAA-3′) and PCR products were
analyzed in agarose gels.
For quantitative real-time PCR (RT-qPCR), isolation of RNA and cDNA
preparation was performed as above. PCR reactions (25 μl) contained 20 ng of
cDNA, 0.25 μM amplification primers, and 12.5 μl of 2× SYBR Green Mastermix
(Applied Biosystems, Foster City, CA). RT-qPCR was performed in a 7900 HT
FAST Real Time PCR System thermocycler (Applied Biosystems). Denaturation at
95 °C for 10 min was followed by 40 cycles of 15 s at 95 °C, and 1 min at 60 °C. The
pairs of primers specific for rat transcripts are 5′-AACTGTCACAAACGCTGTGC-
3′ and 5′-TTGTCATCGCTCCCTTCTTC-3′ to Prkd1, 5′-TGTCTGAAATCCTC
GCAGTG-3′ and 5′-TCTCAAAGCAGTGTG-GGTTG-3′ to Prkd2, 5′-GGAGGC
ATTGATTCTTCCTG-3′, and 5′-AAAGAGGCATCCACCACAAG-3′ to Prkd3, 5′-
ATTAACGCGCAGATCATGCA-3′ and 5′-CCTCGGTGACGTTCAGATTGT-3′
to Sod2, 5′-AGGCACTGGAACTCGCAATG-3′ and 5′-AAGGGCCCGAACAT
ACGATT-3′ to Bdnf. Data were normalized to rat Gapdh and mRNA abundance
was calculated using the ΔΔCT method.
Generation of PKD1 mutant and cloning in a lentiviral vector for neurospecific
expression. Mutant PKD1-Y93E/Y469E was generated by overlap PCR using
pBSK-PKD1 mouse cDNA as a template as previously described57. Briefly, a
sequence upstream of PKD1 cDNA corresponding to pBSK and close to the
polylinker and a sequence near to the SphI site within PKD1 were used as external
forward (5′-GACTCACTATAGGGCGAATTGGGTACCG-3′) and reverse (5′-
CTTGGGGATGACGGGCATAAGAGC-3′) primers together with internal com-
plementary forward (5′-TCCCCGAATGTGGTTTCGAGGGACTCTATGATAAG
ATC-3′) and reverse (5′-GATCTTATCATAGAGTCCCTCGAAACCACATTCGG
GGA-3′) primers containing the residue substitution for Y93E (bold). After the
second PCR reaction, the amplified fragment was digested with XhoI and SphI, and
the wild-type PKD-XhoI/SphI fragment was then replaced. For double mutant
PKD1-Y93E/Y469E, we followed the same approach, using as template pBSK-
PKD1-Y93E mutant and internal primers forward (5′-ACAGGGAGCCGGTA
CGAGAAGGAAATTCCTTTATCAGAA-3′) and reverse (5′-TTCTGATAAAGG
AATTTCCTTCTCGTACCGGCTCCCTGT-3′) containing Y469E substitution
(bold). The quadruple mutant PKD1-Y93E/Y469E/S744E/S748E was obtained by
digesting pBSK-PKD1-Y93E/Y469E with XhoI and SphI, and using this fragment to
substitute that of pBSK-PKD1-S744E/S748E (a mutant obtained before)57. This
quadruple mutant was digested with EcoRI and subcloned in p-EF-Bos-GFP as we
have previously done58. Then, FL fusion sequence GFP-PKD1-Y93E/Y469E/S744E/
S748E was PCR amplified using forward (5′-GGCCTAGGTCACCATGGTGAGC
AAGGGCGAGGA-3′) and reverse (5′-GGTTAATTAATCAGAGGATGCTGAC
ACGCTCACTG-3′) primers containing AvrII and PacI sites, respectively (under-
lined). Once digested, the PCR product was cloned in a lentiviral vector bearing
human Synapsin promoter (SYNpr) SYNpr-DsRed-SYN-GFP59, where DsRed had
been depleted after digestion with BamHI and NotI and substituted by an adaptor
with multiple cloning sites containing AvrII and PacI sites (5′-GATCCCCTAGGC
GCGTTAATTAAGTTTAAACCTCGAGGC-3′ and 5′-GGCCGCCTCGAGGTTT
AAACTTAATTAACGCGCCTAGGG-3′; underlined). The second SYNpr and the
GFP cassette were also eliminated by digestion with SphI and EcoRI, klenow
refilling and religation. Constructs were sequenced using an Applied Biosystems
automated DNA sequencer (ThermoFisher Scientific).
In vitro kinase assays. HEK-293T cells were transfected with p-EF-Bos-GFP
empty or containing wild-type PKD1 (GFP-PKD1), a kinase-dead mutant (GFP-
PKD1-KD) or the quadruple mutant generated here with constitutive kinase
activity (GFP-PKD1-Ca) for 48 h. Total lysates were immnunoprecipitated with
anti-GFP antibodies and PKD1 kinase activity was assessed by in vitro kinase assay
as described previously57. Briefly, immunoprecipitates were washed four times with
RIPA buffer and twice with kinase buffer (30 mM Tris-HCl, pH 7.6, 10 mMMgCl2,
2 mM dithiothreitol) containing [γ-32P]ATP and incubated for 10 min at 30 °C.
The reaction was stopped by adding sample buffer and immunoprecipitates were
resolved by SDS–PAGE and transferred to nitrocellulose membranes. Filters were
exposed to obtain autoradiography images and then subjected to immunoblot
analysis with anti-GFP antibody.
Plasmids for shRNA. Lentiviral vectors containing shRNAs to interfere Dusp1
(shDUSP1) or Step (shSTEP) expression were generated by cloning the following






GCCTGCC-3′. Control shRNA vector (shC) was constructed by introducing oli-
gonucleotides that do not match any known rat transcript: 5′-TCAACAAGATGA
AGAGCACCAATTCAAGAGATTGGTGCTCTTCATCTTGTTGTTTTTTC-3′
and 5′-TCGAGAAAAAACAACA AGATGAAGAGCACCAATCTCTTGAATT
GGTGCTCTTCATCTTGTTGA-3′. The targeted Dusp1 sequence corresponds to
Fig. 7 In vivo neuroprotection by PKD1-Ca from KA-induced hippocampal neuronal death. a Adult male Wistar rats were stereotaxically grafted in the
hippocampal CA1 region with GFP (right hemisphere) or PKD-Ca (left hemisphere) lentivirus. (Right panel) Scheme of the KA injection protocol used. After
12 days of lentiviral grafting, rats were treated with saline or KA (8.5 mg per kg, i.p.) and killed 3 days later. b, c Two consecutive brain series were double
stained with NF-κB or NeuN and anti-GFP antibodies to identify transduced neurons in CA1. b Representative confocal images and zoom-boxed regions are
shown from saline treated animals (n= 6 sections per animal, n= 3 animals). c Representative confocal images from right and left CA1 regions in the same
slice from an animal treated with KA (n= 6 sections per animal, n= 4 animals). See zoom-boxed regions for details of nuclear staining of NeuN and NF-κB,
showing it is more preserved in PKD1-Ca-transduced neurons (right panels) compared to the contralateral side GFP-transduced neurons (left panels). d
Representative FluoroJade B staining from brain slices showing neuronal death at the CA1 region from saline (n= 3) and KA-treated (n= 4) animals. (Right
panel) Quantification of neuronal death as the percentage of FluoroJade B signal in the right or left hemisphere in KA-treated animals (n= 6 sections per
animal, n= 4 animals). Data are expressed as mean + s.e.m. analyzed with two-tailed unpaired Student's t test. **P< 0.01. e Scheme illustrating the role of
PKD in healthy or degenerating neurons. Healthy neurons present basal moderate levels of active PKD and IKK. In this condition, IKK controls IκB
phosphorylation and proteasomal degradation, and NF-κB localizes at the nucleus. Nuclear NF-κB activates Sod2 transcription, increasing SOD2 levels to
facilitate ROS elimination. In excitotoxic neurodegeneration, high concentrations of glutamate overstimulate NMDARs and KARs, and drive PKD
dephosphorylation and inactivation through the induction of PP1 and DUSP1 phosphatases. This step contributes to the shut-off of the IKK/NF-κB/SOD2
axis, decreasing SOD2 levels, and promoting ROS accumulation, oxidative damage and neuronal death
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rat mRNA positions 782–804 and Step sequence corresponds to rat mRNA posi-
tions 1320–1342. The integrity of these novel constructs was verified by sequen-
cing. The two Prkd1 shRNA lentiviral vectors (a and b) and the one for Prkd2 were
obtained from Sigma-Aldrich.
Lentiviral production and transduction of neuronal cultures. Lentiviral sus-
pensions were prepared in HEK293T cells as previously described23. Briefly,
HEK293T were transfected with lentiviral vectors and packaging vectors using
Lipofectamine 2000 reagent and OPTI-MEM media (ThermoFisher Scien-
tific Gibco) for 4 h following the manufacturer instructions. Medium was then
changed to IMDM complemented with 5% fetal bovine serum, 5% horse serum,
22.2 mM glucose, 0.1 mM Glutamax-I (ThermoFisher Scientific Gibco), penicillin
(100 U per ml), and streptomycin (100 U per ml). Supernatant was collected after
48 h. For concentration, the viral suspension was first filtered using a Steriflip-HV
0.45-μm filter unit (Millipore, Billerica, MA, USA) and ultracentrifuged at 20,000
rpm for 2 h at 4 °C in a SW28 Beckman Coulter rotor. Viral pellets were resus-
pended overnight at 4 °C in PBS. HEK-293T cell line was purchased from ATCC
and tested to be mycoplasma-negative. DIV7 neurons were transduced with con-
centrated lentiviral suspensions (107–108 pfu per ml) directly added to the growing
media for 7 additional days.
Assessment of neuronal viability in neuronal cultures. Analysis of neuronal
survival was measured by MTT reduction assay (Sigma-Aldrich), as previously
described23. Briefly, MTT (0.5 mg per ml) was added to the medium of neuronal
cultures, and after 2 h at 37 °C, medium was eliminated and the formazan salts
formed were solubilized in 100 μl of DMSO and spectophotometrically quantified
at 570 nm. Data were represented as the percentage of neuronal viability giving to
the control conditions a 100% value. Neuronal death was also analyzed by deter-
mining nuclear condensation and neuronal shape, visualized by DAPI and
MAP2 staining, respectively, and expressed as percentage of nuclear condensation.
Viability of neurons transduced with GFP or PKD1-Ca lentiviral particles was
expressed as the percentage of GFP+ neurons after NMDA or KA treatments
relative to control untreated neurons taken as 100% viability.
Determination of ROS production in cultured neurons. Rat cortical neurons
DIV14 were treated with NMDA for 1 h and then washed and loaded with 10 μM
Cell ROX Deep Red Reagent fluorogenic probe (ThermoFisher Scientific), by
incubating them at 37 °C for 30 min in the dark. The medium was removed and
cells were washed once with PBS, trypsinised and collected. Then, cells were
washed twice with PBS and fixed with 4% PFA for 10 min at room temperature.
Cellular fluorescence intensity was measured on a FACSCanto II flow cytometer
(BD Biosciences, Allschwil, Switzerland). For each analysis, 10,000 events were
recorded. ROS production was estimated using the mean fluorescence intensity of
each cell population. In neurons transduced with GFP or PKD1-Ca, the mean of
the fluorescence intensity relative to the total of GFP+ population was measured.
Cultures of mouse cortical neurons from PKD1floxed and PKD1-KO mice were
treated with NMDA for 1 h and then washed and loaded with 10 μM
dihydroethidium (DHE, ThermoFisher Scientific), by incubating them at 37 °C for
30 min in the dark. The medium was removed and cells were washed once with
PBS, trypsinised, and collected. Then, cells were washed twice with PBS and
fluorescence intensity was measured by flow cytometry as above. For each analysis,
10,000 events were recorded. ROS production was estimated using the mean
fluorescence intensity of each cell population. In addition, DHE staining of neurons
seeded onto coverslips was also analyzed by confocal microscopy.
Luciferase assays. Cortical neurons plated in 24-well plates were transfected at
DIV7 with (NF-κB)3-tk-Luc or tk-Luc, together with renilla luciferase plasmids.
Cells were transfected in serum-free medium by using 0.5 μg of DNA and 0.5 μl of
Lipofectamine 2000 reagent (Invitrogen) per well, according to the manufacturer’s
specifications. Two days after transfection, neurons were treated with NMDA for 3
h and processed for luciferase activity measurements. Luciferase activity was
detected by adding the enzyme substrate provided in the Dual-GloTM luciferase
assay system (Promega Corporation), according to the manufacturer’s instructions.
The samples were assayed on a Veritas microplate luminometer (Turner BioSys-
tems Inc., California, USA).
Ca2+ measurements. Single-cell Ca2+ levels in cortical neurons transduced with
GFP or GFP-PKD1-Ca lentiviral particles were recorded using the ratiometric Ca2+
indicator dye Fura Red acetoxymethyl ester (ThermoFisher Scientific). Cells were
grown on eight-well chamber slides and loaded with 5 μM Fura Red, AM for 30
min at 37 °C in HBSS containing 145 mM NaCl, 5 mM KCl, 0.75 mM Na2HPO4,
10 mM glucose, 10 mM HEPES (pH 7.4), 1 mM MgCl2, and 2 mM CaCl2 (high Ca2
+ medium), and then rinsed and left undisturbed for 30 min at 37 °C to allow for
de-esterification. Measurements of intracellular Ca2+ levels were performed every
second at 37 °C using a Confocal LSM510 META microscope (Zeiss, Germany).
Changes in intracellular Ca2+ concentration ([Ca2+]i) in individual neuronal cell
bodies are expressed as the F458/F488 ratio after subtracting background fluor-
escence. This ratio represents the emission intensities at 660 nm obtained after
excitation at 458 and 488 nm. Cells that responded rapidly to NMDA stimulation
were identified as neurons and only GFP+ neurons were analyzed. Data processing
was performed using ImageJ software.
Immunofluorescence of cultured neurons. Primary neurons grown on coverslips
were fixed with 4% PFA with 4% sucrose, permeabilised with 0.1% Triton X-100 in
PBS for 5 min and then incubated in 4% bovine serum albumin in PBS for 30 min.
Coverslips were then incubated for 1 h at room temperature with the appropriate
primary antibody in blocking solution followed by the corresponding secondary
antibody. The nuclei were stained with DAPI and coverslips were mounted with
Prolong medium (ThermoFisher Scientific).
Immunohistochemistry of rat and mouse and human brain samples. Rats and
mice were anesthetized by an i.p. injection of pentobarbital and then perfused with
4% PFA. Brains were removed and post-fixed in 4% PFA overnight and cryo-
protected in 30% sucrose in PBS for 48 h before freezing. Thirty μm-thick coronal
sections were obtained by a Cryostat (Leica Microsystems, Germany). Floating
coronal sections were incubated in blocking solution (1% BSA, 1% Triton X-100 in
0.1 M PBS) with primary antibodies overnight at 4 °C and subsequently incubated
2 h at 4 °C with secondary antibodies. Then, slices were rinsed in PBS and nuclei
were stained with DAPI and mounted with Prolong medium.
In a complete series of coronal brain sections from KA-treated rats injected with
lentivirus, transduced neurons were identified in the CA1 hippocampal region by
immunostaining using anti-GFP antibodies. The same series of sections was also
co-stained for NeuN and NF-κB. All sections containing GFP signal were analyzed
by confocal microscopy imaging for NeuN and NF-κB. An additional series of
sections was mounted on slides for Nissl staining with cresyl violet to see KA-
induced neuronal death at the CA1 hippocampal area.
Complete series of coronal sections from PKD1floxed and PKD1-KO mice were
stained free-floating using the biotin–avidin peroxidase method and 3-3ʹ
diaminobenzidine (DAB; Sigma FAST DAB, Sigma-Aldrich) as a chromogen.
Selected pictures correspond to coronal slices from the rostral region of brain
cortex (Bregma +1.34 mm to −0.84 mm). Endogenous peroxidase was inactivated
by incubating sections in a solution of 0.3% hydrogen peroxide in PBS for 30 min.
Brain sections were pretreated for 1 h with 1% BSA, 5% FBS, and 0.2% Triton X-
100 in PBS, and subsequently incubated with rabbit polyclonal antibodies against
PKD and phospho-PKD-S916. Finally, brain sections were incubated with
avidin–biotin complex using Elite Vectastain kit (Vector Laboratories, Burligame,
CA, USA). Chromogen reactions were performed with DAB and 0.003% hydrogen
peroxide for 10 min before mounting with Prolong medium.
Complete series of coronal sections from Sham- and MCAO-operated wild-type
mice or PKD1floxed and PKD1-KO animals were Nissl stained to identify slices that
contained areas of ischemic damage and corresponded to ischemic areas initially
identified by T2W MRI. Additional series of slices were also stained for the analysis
of the different markers (NeuN, and p-PKD or NF-κB or MDA) by confocal
microscopy. To assess the histological sections in a stereological fashion, the
anatomical extent of neuronal injury in the ischemic hemisphere was defined based
on the NeuN staining, showing damage in infarcted areas. The regions containing
neuronal injury were not well captured by standard anatomical definitions, so
specific regions of interest (ROI) boundaries were determined in the cortex
adjacent to the nucleus of the infarct for each coronal slice. Specifically, the ROI
was defined by blinded observers in the rostral region containing the striatum and
primary somatosensorial cortex and primary motor cortex (Bregma +1.34 mm to
−0.84 mm)60 and whose boundaries were the external capsule, the secondary motor
cortex and the granular insular cortex. The ischemic core localized extensively in
the striatal area, where no NeuN, and p-PKD or NF-κB signal was detected,
hindering any quantitative analysis of this region. Quantification studies were
performed in the penumbra area of three independent selected sections per animal
after defining ROI boundaries as explained above.
Paraffin-embedded human postmortem stroke 15-μm sections were processed,
treated with citrate buffer (pH 6.0) for antigen retrieval, and incubated in 10%
donkey serum for 1 h. For double immunofluorescence analysis, sections were
incubated with primary antibodies for 2 days in blocking solution followed by
washes in PBS and incubation with secondary antibodies in the same solution.
Then, slices were rinsed in PBS and nuclei were stained with DAPI. Sections were
treated with a saturated solution of Sudan black B (Merck Bioscience, Darmstadt,
Germany) for 15 min to block autofluorescence of lipofuscin granules. The sections
were later washed and mounted with Prolong medium.
FluoroJade B staining of rat brain. To quantify brain damage in KA-treated rats,
a different set of coronal brain sections adjacent to that used for immuno-
fluorescence analysis was stained for in situ cell death using FluoroJade B staining
(Millipore Corporation, Billerica, MA, USA). It is important to point out that we
confirmed that GFP fluorescence was not affecting FluoroJade B staining. For that
purpose, we combined FluoroJade B labeling with GFP immunostaining using an
anti-GFP antibody detected with a secondary Alexa-555 antibody and found
absolutely no co-localization of both signals by confocal microscopy analysis. For
FluoroJade B staining, sections were mounted in superfrost slides and incubated for
3 min with absolute ethanol followed by 1 min in 70% ethanol. After rinsing in
H2O, slides were immersed in 0.06% KMnO4 for 15 min in the dark. Then, slides
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02322-5
16 NATURE COMMUNICATIONS |  (2017) 8:2275 |DOI: 10.1038/s41467-017-02322-5 |www.nature.com/naturecommunications
were extensively washed in H2O and transferred to a staining solution containing
0.1% acetic acid and 0.0004% FluoroJade B for 30 min in the dark. Slides were
again rinsed in H2O, dried, and submerged directly into xylene and mounted in
DPX medium (Sigma-Aldrich). For quantification analysis, CA1 regions were
outlined, and total FluoroJade B staining in the outlined region was measured using
a densitometric thresholding technique implemented with ImageJ 1.47d software
(NIH). The threshold was set at a level just above that with counted background
and non-specific staining in areas outside the outlined region. The analysis was
done in a series of sections through the entire hippocampus from each rat brain.
Data were represented as the % FluoroJade B staining and indicate the total
number of stained pixels over threshold.
Brain vascular anatomy. PKD1floxed and PKD1-KO mice littermates brain vas-
cular anatomy was analyzed as described61. Briefly, mice were anesthetized by an i.
p. injection of pentobarbital and then 2 ml of 5% Evans blue solution in saline was
perfused intracardially for 1 min. Animals were killed and brains were fixed by
immersing the skulls in 4% PFA for 48 h. Macroscopic images of ventral and dorsal
views of the brain were acquired under a stereo microscope (M50, Leica, Germany)
under cold light illumination using a digital camera (Infinity 2 Digital Camera,
Nikon). Quantification of dorsal surface brain images was performed with ImageJ
software, measuring the distance between the anastomotic line, drawn as previously
described62, and the midline at 3 and 6 mm from the frontal pole of the brain.
Images acquisition. Confocal microscopy images were acquired using plan-
apochromatic objectives in an inverted Zeiss LSM 710 laser scanning microscope
(Zeiss, Germany). To avoid crosstalk between channels, sequential scanning mode
was used. All images shown correspond to the maximum intensity projection of
serial sections; in case of different projections, details can be found in figure
legends. Pictures were processed with Zen 2009 (Carl Zeiss MicroImaging), Adobe
Photoshop CS (Adobe Systems Inc.), and ImageJ 1.47d (NIH) software. Nissl and
DAB staining bright field images were captured in a Nikon Eclipse 90i microscope,
using a Digital Sight DS-QiMc camera and NIS-Elements BR 3.0 software.
Quantitative and statistical analysis. Immunoblot signals were quantified by
densitometric analysis (NIH Image) and normalized using NSE. Phospho-antibodies
signals were normalized using the total protein values relative to those of NSE. Data
were expressed relative to values obtained in their respective untreated controls.
Neuronal viability in cortical cultures was measured by MTT or DAPI condensation.
Three independent experiments were quantified in MTT assays. The mean of these
experiments was represented as the % of neuronal viability giving a 100% value to the
control conditions. DAPI condensation was quantified counting 120–250 cells and
expressed as the % of nuclear condensation relative to the total number of cells for
each condition. Neuronal viability in cortical neurons transduced with GFP or PKD1-
Ca was performed counting the number of GFP+ cells relative to the total number of
neurons present in control conditions taken as 100% viability. Nuclear localization of
NF-κB in neuronal cultures was analyzed by manual counting the presence or absence
of the protein in the nuclei of 50–100 neurons (MAP2+ cells) per sample relative to
control untreated cells. In neurons transduced with GFP or PKD1-Ca, we counted the
number of cells with nuclear NF-κB in 50–100 GFP+ cells and represented it relative
to the total number of cells for each condition. For the analysis of immunohis-
tochemistry in MCAO-operated mice, the intensity of p-PKD-S916 and NF-κB
staining was measured in 100 NeuN+ neurons and compared to the value of the mean
obtained from sham-operated animals. In human samples, the presence or absence of
p-PKD-S916 and NF-κB staining was analyzed by manual counting in 30–50 NeuN+
neurons for each condition (control and ischemic stroke). Analyses of significant
differences between means were carried out using unpaired or paired two-tailed
Student's t test with Welch's correction when appropriated. No statistical method was
used to predetermine sample size. Sample sizes were based on previously published
experiments by us and others, and on our own unpublished data. The experiments
were not randomized. The investigators were not blinded to allocation during
experiments or outcome assessment. Results are shown as mean± s.e.m. and the
number of experiments carried out with independent primary neuronal cultures and
animals (n) is shown in figure legends.
Data availability. The data sets generated and/or analyzed during the current
study are available from the corresponding author on reasonable request.
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